- Date of the Event: 9 Mar 2017
- Company Name: OBI Pharma, Inc
- Relationship to the Company (enter “Parent” or “Subsidiary”: Parent
- Reciprocal shareholding ratios: N/A
- Reason for the Event: The Company’s 2016 individual and consolidated financial statements were
approved by the board of directors. Essential financial items are presented below.- From the 2016 Individual Financial Statement
– Operating loss: (NT$ 1,110,256,000)
– Total comprehensive loss for the period: (NT$ 1,111,256,000)
– Loss Per Share (in dollars): (NT$ 6.51) - From the 2016 Consolidated Financial Statement
– Operating loss: (NT$ 1,112,470,000)
– Total comprehensive loss for the period: (NT$ 1,111,256,000)
– Loss Per Share (in dollars): (NT$ 6.51)
- From the 2016 Individual Financial Statement
- Countermeasures: N/A
- Any other matters that need to be specified: None